HEIDELBERG, Germany - Apogenix, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, today announced in a press release that the European Patent Office has granted the Company a patent for the use of CD95 ligand inhibitors including APG101 in the treatment of myelodysplastic syndromes (MDS). The patent covers the use of such inhibitors in low to intermediate-1 risk transfusion-dependent MDS patients and is valid until July 2033.  

While Apogenix already holds a broad patent portfolio covering APG101, including composition of matter as well as manufacturing and method of treatment of glioblastoma, this is the first patent to cover its clinical use specifically in MDS patients.   

“The granting of this additional patent for APG101 further validates our innovative drug development approach and strengthens the protection of our most advanced asset,” said Thomas Hoeger, Ph.D., CEO of Apogenix. “With the recently announced positive results from the Phase I trial in MDS patients, we now intend to further develop APG101 in this indication, for which today there are no sufficient treatment options available.” 

The recently completed Phase I trial evaluated APG101 in low to intermediate-1 risk transfusion-dependent MDS patients and demonstrated the tolerability as well as activity of the drug candidate: APG101 treatment stimulated erythropoiesis and led to a significant decrease in transfusion frequency in this patient population.  

To further evaluate the efficacy and safety of APG101 in the treatment of MDS patients, Apogenix is currently in preparation of Phase II proof-of-concept trials.  

  

.